Joshua Feder, MD

Assessment of Non-Suicidal Self-Injury in Children and Adolescents

March 12, 2023

Joshua Feder, MD, Mara Goverman, and Hanni Flaherty, LCSWR, PhD, CASAC

Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

Addressing Sensory Processing Challenges

February 12, 2023

Joshua Feder, MD and Mara Goverman

Learn to identify sensory challenges to address these barriers to effective care in teens and adolescents.

Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

PDF Access and 10 CME Post-Test

January 20, 2023

Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

This page has links and instructions for downloading your PDF and eBook copies of the Child Medication Fact Book for Psychiatric Practice and completing the 10 CME Post-Test.

Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

PDF Access and 10 CME Post-Test

January 20, 2023

Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

This page has links and instructions for downloading your PDF and eBook copies of the Child Medication Fact Book for Psychiatric Practice and completing the 10 CME Post-Test.

Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

PDF Access and 10 CME Post-Test

January 20, 2023

Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

This page has links and instructions for downloading your PDF and eBook copies of the Child Medication Fact Book for Psychiatric Practice and completing the 10 CME Post-Test.

RESEARCH UPDATE

SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

October 1, 2022

Joshua Feder, MD

Dr. Feder, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.

Note from the Editor-in-Chief

July 1, 2022

Joshua Feder, MD

Josh Feder, MD.

Editor-in-Chief of The Carlat Child Psychiatry Report.

In 2015 at my first Graphic Medicine conference (www.graphicmedicine.org), clinicians and patients spoke about the daily hurt people experience with fat shaming, some to the point of suicidality. It’s one thing to see it but another to fight it. Our interview with Dr. Sarah Nutter helps us combat weight bias.

Note From the Editor-in-Chief

October 30, 2020

Joshua Feder, MD

Josh Feder, MD Dr. Feder has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With a surging pandemic and cultural turmoil, we are all working as best we can. At Carlat, we are striving to give you what you need to keep going. Every clinician needs to prepare for disasters, even if that is mainly knowing how to support your own patients when disaster...

Note From the Editor-in-Chief

June 26, 2019

Joshua Feder, MD

Joshua Feder, MD

In this double issue, we tackle a range of questions. First, does TMS help kids and teens with depression? Is it safe? Since many clinics are advertising TMS, we thought it was worth a close look.

FDA Approves Adhansia XR

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.